Cargando…

Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with Stable Coronary Artery Disease: A Cross-Sectional Study

A recent experimental study suggested that proton pump inhibitors (PPI), widely used to prevent gastroduodenal complications of dual antiplatelet therapy, may increase the accumulation of the endogenous nitric oxide synthesis antagonist asymmetric dimethylarginine (ADMA), an adverse outcome predicto...

Descripción completa

Detalles Bibliográficos
Autores principales: Kruszelnicka, Olga, Świerszcz, Jolanta, Bednarek, Jacek, Chyrchel, Bernadeta, Surdacki, Andrzej, Nessler, Jadwiga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848910/
https://www.ncbi.nlm.nih.gov/pubmed/27092494
http://dx.doi.org/10.3390/ijms17040454
_version_ 1782429445856952320
author Kruszelnicka, Olga
Świerszcz, Jolanta
Bednarek, Jacek
Chyrchel, Bernadeta
Surdacki, Andrzej
Nessler, Jadwiga
author_facet Kruszelnicka, Olga
Świerszcz, Jolanta
Bednarek, Jacek
Chyrchel, Bernadeta
Surdacki, Andrzej
Nessler, Jadwiga
author_sort Kruszelnicka, Olga
collection PubMed
description A recent experimental study suggested that proton pump inhibitors (PPI), widely used to prevent gastroduodenal complications of dual antiplatelet therapy, may increase the accumulation of the endogenous nitric oxide synthesis antagonist asymmetric dimethylarginine (ADMA), an adverse outcome predictor. Our aim was to assess the effect of PPI usage on circulating ADMA in coronary artery disease (CAD). Plasma ADMA levels were compared according to PPI use for ≥1 month prior to admission in 128 previously described non-diabetic men with stable CAD who were free of heart failure or other coexistent diseases. Patients on PPI tended to be older and with insignificantly lower estimated glomerular filtration rate (GFR). PPI use was not associated with any effect on plasma ADMA (0.51 ± 0.11 (SD) vs. 0.50 ± 0.10 µmol/L for those with PPI (n = 53) and without PPI (n = 75), respectively; p = 0.7). Additionally, plasma ADMA did not differ between PPI users and non-users stratified by a history of current smoking, CAD severity or extent. The adjustment for patients’ age and GFR did not substantially change the results. Thus, PPI usage does not appear to affect circulating ADMA in non-diabetic men with stable CAD. Whether novel mechanisms of adverse PPI effects on the vasculature can be translated into clinical conditions, requires further studies.
format Online
Article
Text
id pubmed-4848910
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-48489102016-05-04 Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with Stable Coronary Artery Disease: A Cross-Sectional Study Kruszelnicka, Olga Świerszcz, Jolanta Bednarek, Jacek Chyrchel, Bernadeta Surdacki, Andrzej Nessler, Jadwiga Int J Mol Sci Article A recent experimental study suggested that proton pump inhibitors (PPI), widely used to prevent gastroduodenal complications of dual antiplatelet therapy, may increase the accumulation of the endogenous nitric oxide synthesis antagonist asymmetric dimethylarginine (ADMA), an adverse outcome predictor. Our aim was to assess the effect of PPI usage on circulating ADMA in coronary artery disease (CAD). Plasma ADMA levels were compared according to PPI use for ≥1 month prior to admission in 128 previously described non-diabetic men with stable CAD who were free of heart failure or other coexistent diseases. Patients on PPI tended to be older and with insignificantly lower estimated glomerular filtration rate (GFR). PPI use was not associated with any effect on plasma ADMA (0.51 ± 0.11 (SD) vs. 0.50 ± 0.10 µmol/L for those with PPI (n = 53) and without PPI (n = 75), respectively; p = 0.7). Additionally, plasma ADMA did not differ between PPI users and non-users stratified by a history of current smoking, CAD severity or extent. The adjustment for patients’ age and GFR did not substantially change the results. Thus, PPI usage does not appear to affect circulating ADMA in non-diabetic men with stable CAD. Whether novel mechanisms of adverse PPI effects on the vasculature can be translated into clinical conditions, requires further studies. MDPI 2016-04-15 /pmc/articles/PMC4848910/ /pubmed/27092494 http://dx.doi.org/10.3390/ijms17040454 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kruszelnicka, Olga
Świerszcz, Jolanta
Bednarek, Jacek
Chyrchel, Bernadeta
Surdacki, Andrzej
Nessler, Jadwiga
Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with Stable Coronary Artery Disease: A Cross-Sectional Study
title Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with Stable Coronary Artery Disease: A Cross-Sectional Study
title_full Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with Stable Coronary Artery Disease: A Cross-Sectional Study
title_fullStr Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with Stable Coronary Artery Disease: A Cross-Sectional Study
title_full_unstemmed Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with Stable Coronary Artery Disease: A Cross-Sectional Study
title_short Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with Stable Coronary Artery Disease: A Cross-Sectional Study
title_sort asymmetric dimethylarginine versus proton pump inhibitors usage in patients with stable coronary artery disease: a cross-sectional study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848910/
https://www.ncbi.nlm.nih.gov/pubmed/27092494
http://dx.doi.org/10.3390/ijms17040454
work_keys_str_mv AT kruszelnickaolga asymmetricdimethylarginineversusprotonpumpinhibitorsusageinpatientswithstablecoronaryarterydiseaseacrosssectionalstudy
AT swierszczjolanta asymmetricdimethylarginineversusprotonpumpinhibitorsusageinpatientswithstablecoronaryarterydiseaseacrosssectionalstudy
AT bednarekjacek asymmetricdimethylarginineversusprotonpumpinhibitorsusageinpatientswithstablecoronaryarterydiseaseacrosssectionalstudy
AT chyrchelbernadeta asymmetricdimethylarginineversusprotonpumpinhibitorsusageinpatientswithstablecoronaryarterydiseaseacrosssectionalstudy
AT surdackiandrzej asymmetricdimethylarginineversusprotonpumpinhibitorsusageinpatientswithstablecoronaryarterydiseaseacrosssectionalstudy
AT nesslerjadwiga asymmetricdimethylarginineversusprotonpumpinhibitorsusageinpatientswithstablecoronaryarterydiseaseacrosssectionalstudy